MANGROVE PARTNERS IM, LLC
Position in SLS — SELLAS Life Sciences Group, Inc.
CIK 1535392
Greenwich, CT
Position in SLS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$503,906
New position
Shares Held
34,140
first reported quarter
Ownership
0.017%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#88
of 189 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026MANGROVE PARTNERS IM, LLC holds $8,126,934 across 17 Biotechnology names. SLS ranks #7 (6.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MIRM |
Mirum Pharmaceuticals, Inc.
|
9,916 | $1,160,866 | |
| 2 | DYN |
Dyne Therapeutics, Inc.
|
47,927 | $1,064,458 | |
| 3 | ALT |
Altimmune, Inc.
|
239,280 | $727,411 | |
| 4 | FBRX |
Forte Biosciences, Inc.
|
33,346 | $708,602 | |
| 5 | ARVN |
Arvinas, Inc.
|
76,220 | $633,388 | |
| 6 | LENZ |
LENZ Therapeutics, Inc.
|
96,749 | $549,534 | |
| 7 | SLS |
SELLAS Life Sciences Group, Inc.
This page
|
34,140 | $503,906 | |
| 8 | RLMD |
Relmada Therapeutics, Inc.
|
71,705 | $496,198 |
All Filings in SLS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $503,906 | 34,140 | Shares | Sole | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||